Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Publicized Settlement ...

I would be willing to bet the vast majority of shareholders would be in favor of risking everything at a trial and not settling for anything with the T3 unless the dollars were significant and publicized to the industry.

That would represent 50% of the MMP ownership. That should be enough to force TPL's hand.

Is the BOD representing shareholders in this regard? Did they negotiate with TPL to force TPL to go to trial, or settle for a large, published settlement amount?

Shareholders want the MMP pushed to the end. They want finality.

Share
New Message
Please login to post a reply